ondansetron has been researched along with Hakim Syndrome in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron was the only medication administered that had previously been associated with dystonic reactions." | 1.42 | Dystonic reaction associated with ondansetron administration in a patient with normal pressure hydrocephalus. ( Diaz-Parlet, J; Subramani, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diaz-Parlet, J | 1 |
| Subramani, S | 1 |
1 other study available for ondansetron and Hakim Syndrome
| Article | Year |
|---|---|
Dystonic reaction associated with ondansetron administration in a patient with normal pressure hydrocephalus.
Topics: Aged; Anesthesia, General; Dystonia; Female; Humans; Hydrocephalus, Normal Pressure; Intracranial Pr | 2015 |